The central figure in Nestlé's $2.6B Aimmune buyout? Covid-19
Nestlé surprised few this summer when they spent $2.6 billion to buyout Aimmune. The Swiss Butterfingers-and-health conglomerate had long shown more interest in them and Palforzia, their recently approved peanut allergy treatment, than any of the traditional Big Pharmas.
When talks began, though, in the second quarter, Aimmune was only looking for a partner to help them commercialize the therapy in Europe. In fact, as part of its series of investments in the company, Nestlé had signed a “Standstill Agreement,” that would prevent them from acquiring the biotech until November 202o.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
